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Mitochondrial DNA and aging 
Osteoarthritis (OA) is the most common form of arthritis affecting more than 12% of people 
over the age of 60 (1). Although late-onset articular cartilage degeneration is common and 
age is one of the most important risk factors for the disease, the relationship between old 
age and OA is not fully understood (2). In the past it was believed that the link with age was 
due to “wear and tear” of articular cartilage by continuous mechanical stress; we now know, 
however, that OA involves an active response to injury comprising remodelling of articular 
cartilage and subchondral bone, in addition to synovial inflammation and damage to other 
joint structures such as ligaments and menisci (3).  
Biological aging is a complex process and it is now is widely accepted that aging starts with 
molecular damage, leading to cell, tissue, and, ultimately, organ dysfunction (4). Extensive 
evidence from animal models and in vitro studies indicates that mitochondria contribute to 
specific aspects of the aging process, including cellular senescence, chronic inflammation, 
and the age-dependent decline in stem cell activity (5). 
Perhaps the best known and most long-standing hypothesis to explain aging is the free 
radical theory, which proposes a central role for the mitochondrion as the principle source of 
intracellular reactive oxygen species (ROS) leading to mitochondrial DNA (mtDNA) 
mutations (4-5). Somatic (acquired) mtDNA mutations and their association with the decline 
in mitochondrial function during aging are well described, but  these observations do not 
necessarily imply a causal relationship between mitochondrial dysfunction and human aging.  
The maternally inherited mtDNA sequences encode the key proteins involved in energy 
production, although the relevance of high sequence variability of mtDNA had been 
considered of little functional relevance.  Latorre-Pellicer and co-authors showed recently 
that transferring mtDNA from a mouse strain to the nuclear DNA (nDNA) background of 
another strain results in huge differences in insulin signalling, obesity, and longevity 
throughout the life of the mouse (6). The two mtDNA sequences differ in genetic variants 
that confer 12 amino-acid substitutions and 12 changes in RNA molecules involved in 
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mitochondrial protein synthesis; this level of variation is enough to result in striking 
differences in the ROS generation, insulin signalling, obesity, and cell-senescence related 
parameters such as telomere shortening and mitochondrial dysfunction.  Showing the direct 
relevance of mtDNA in human aging and in age-related diseases such as OA is a big 
challenge and one which is, at least in part, addressed in this issue of the Annals of the 
Rheumatic Diseases (7). 
mtDNA in OA 
Over the past 10 years, the group led by Francisco Blanco and Ignacio Rego-Perez has 
shown that differences in mtDNA haplogroups correspond to variations in the prevalence 
and progression of cartilage loss in large joint OA (8). In a series of studies from Spanish OA 
cases and controls, the evidence has accumulated for an association between OA 
prevalence and the J haplogroup  (9-10) (Table 1). However, two studies in samples from 
the UK have failed to find an association with the J haplotype (9-11), whereas evidence of 
association of the T haplotype with lower disease risk was found in a small UK cohort (9) 
(Table 1). 
The mtDNA haplogroups J and T share the same phylogenetic origin and a set of common 
uncoupling mitochondrial polymorphisms (12). These uncoupling polymorphisms confer 
different metabolic characteristics compared to other mitochondrial lineages, particularly the 
most common and highly efficient mtDNA haplogroup H. (13) 
The jury is still out regarding the role of mtDNA T and J haplogroups with regard to genetic 
susceptibility in populations with large joint OA, particularly when compared to the evidence 
accumulated for nuclear genetic variants identified from GWAS or otherwise (14). To date, 8 
variants associated with knee OA have been reported with significance of p< 1 x 10-7 and 11 
variants with hip OA in Caucasians. At least three other variants have been reported at high 
significance levels in Asians (see ref 14 for details) 
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On the other hand, with the exception of variants mapping to GDF5 and FTO genes, the 
mechanisms underlying the risk conferred by variants linked to knee OA are yet to be 
unveiled (14). Importantly, as of today very few efforts have been made to identify genetic 
risk factors contributing to risk of progression or incidence of disease.  
The mtDNA haplotypes T, J, and the JT cluster, on the other hand, are significantly 
associated in populations from the US, the Netherlands, and Spain with radiographic 
incidence and progression of the disease (7, 15)  (Table 1). Fernandez-Moreno and co-
authors report that the mtDNA haplogroup J, the same haplogroup associated with lower OA 
prevalence, lower disease progression, and lower cartilage loss, is also associated with a 
significantly lower risk of incident knee OA in a population of 3124 individuals from two 
prospective cohorts from the Netherlands and the US (7). 
Functional analysis of mtDNA variants  
From previous studies it is known that the low OA risk haplogroup J is associated with lower 
serum levels of markers of collagen type II degradation and of matrix metalloproteinases, but 
all of these studies failed to address the key question arising from this large body of 
evidence: “What is the functional role of these mtDNA haplogroups?” 
To answer this question, Fernandez-Moreno and colleagues (7) used cytoplasmic hybrid 
(cybrid) cell lines. Cybrids incorporate mitochondria from human subjects and perpetuate the 
mitochondrial DNA (mtDNA)-encoded components while maintaining the nuclear 
background of different cybrid lines as constant (16). Thus, this technique allows 
investigators to assess the influence of mtDNA variation on cell function. To investigate the 
role of mtDNA haplogroups, they also created cybrids using osteosarcoma cell lines with the 
same nuclear background, one of them harbouring the haplogroup J (which protects against 
OA) and another harbouring the haplogroup H (linked to higher risk of OA). 
The cybrids carrying the haplogroup H produced higher ATP levels than those with the 
haplogroup J, but this higher energetic efficiency was accompanied by higher production of 
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ROS and the proportion of cells that survived in the presence of hydrogen peroxide was 
almost half the number of cybrids with haplogroup J.  In chondrocytes during OA, oxidative 
stress may act together with inflammatory and/or mechanical stress to accentuate catabolic 
processes by increasing the levels of ROS relative to antioxidants .(17-18) The increased 
levels of ROS also contribute to the senescence secretory phenotype, in which the age-
related decline in the responses of chondrocytes to anabolic growth factors are related to 
increased oxidative stress (19-20). The depletion of antioxidants promotes mitochondrial 
dysfunction in chondrocytes (21), which in turn can amplify the stress responses through 
increased production of nitric oxide and ROS and activation of NF-κB signalling (21-23). 
In the presence of staurosporine, which induces cell apoptosis, the cybrids with the 
haplogroup H had over 50% more apoptotic cells than the cybrids with the low OA risk 
haplogroup J (7). These data, therefore, prove the functional relevance of mtDNA variation 
linked to risk of OA on cell function and survival and is in agreement with recent work by the 
same group showing that OA cartilage exhibits signs of early molecular aging compared to 
healthy age-matched cartilage (2). 
Clinical relevance 
The data accumulated on the role mtDNA on cell function and on OA risk has potential 
clinical implications. On the one hand it may allow investigators in the future to define an 
“age-related OA” genetic type (haplogroup H) versus one which is protected from the effects 
of aging. This group with lower incidence and progression can be excluded from clinical 
studies that require rapidly progressing OA populations. At the same time, haplogroup J 
carriers are not fully protected from OA; therefore, studying risk factors in this haplogroup 
can help identify a group of individuals where other molecular mechanisms linked to OA, for 
example, those derived from bone changes or from inflammation, may be stronger predictors 
for progression. These data also raise the important question of the contribution of 
interactions between nuclear DNA and mtDNA haplogroups, which have yet to be 
investigated. Finally, OA is a disease that occurs together with cardiometabolic 
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comorbidities, which are known to be influenced by mitochondrial dysfunction. Haplogroup H 
carriers may therefore be the group of OA sufferers at higher risk of metabolic syndrome and 
cardiovascular disease and with the most chance to benefit from regenerative therapies 
targeting early cartilage damage or, at more advanced stages, early joint replacement. 
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Table 1. Selected associations between T, J and TJ cluster mitochondrial DNA and osteoarthritis prevalence, progression and incidence of OA 
Study Origin Haplogroup Trait studied Total N Effect (95% CI)  
p-value 
Reference 
Case-control Spain J OA prevalence 2557 OA, 1339 controls OR=0.57 (0.46, 0.71) p<0.00001 (10) 
Case-control UK J OA prevalence 7846 OA,  5402 controls OR= 1.19  (0.72- 1.95) n.s. (10) 
Case-control UK T OA prevalence 453 OA, 280 controls OR=0.57 (0.35-0.940 p<0.027 (9) 
CHECK cohort Netherlands T OA progression 431 OA HR= 0.645 (0.419 -0.978) p<0.05 (15) 
OAI USA T OA progression 891 OA HR=0.50 (0.28-0.88) p<0.05 (24) 
Spanish OA cohort Spain T OA progression 281 OA HR=0.69 (0.38, 1.28) n.s. (25) 
Meta analysis  T OA progression 1603 OA HR= 0.61 (0.45-0.82) p=0.001 (15) 
CHECK Netherlands JT OA progression 431 OA HR=0.71 (0.50-0.96) p<0.05 (15) 
OAI USA JT OA progression 891 OA HR=0.81 (0.59-1.11) ns. (15) 
Spanish OA cohort  Spain JT OA progression 281 OA HR=0.80 (0.50-1.26) n.s. (15) 
Meta-analysis  JT  1603 OA HR=0.77 (0.62-0.94) p=0.009 (15) 
CHECK Netherlands J OA incidence 635 HR=0.73 (0.47-1.00) p<0.05 (7) 
OAI USA J OA incidence 2579 HR=0.68 (0.47-0.97) p<0.05 (7) 
Meta-analysis  J OA incidence 3214 HR=0.70 (0.54-0.91) p=0.006 (7) 
 
* OR = odds ratio HR= hazards ratio 
 
